Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure
OncLive TV
Donna L. Berry, from Dana-Farber Cancer Institute, on Symptom Distress and Oral Therapy Adherence.
Advertisement
Dr. Ezra Cohen, from the University of Chicago, Discusses Treating Medullary Thyroid Cancer
Dr. Paul J. Hesketh, from Lahey Clinic Medical Center, on Developing Guidelines and Protocols
Dr. Michael S. Ewer, from The University of Texas MD Anderson Cancer Center, on Supportive Care
Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, Defines Personalized Medicine
Advertisement
Joseph Unger, from the SWOG Statistical Center at the Fred Hutchinson Cancer Research Center, on Low-Income Clinical Trial Participation.
Dr. Richard Gralla, from Quality of Life Research Associates, on Future Advances in chemotherapy-induced nausea and vomiting Prevention
Carrie Stricker, PhD, RN, from Abramson Cancer Center, on Barriers to Adopting Triple Therapy
Steven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.
Dr. Robert Bast, from the MD Anderson Cancer Center, Discusses New Biomarker Panels for Ovarian Cancer Screening.
Paul J. Hesketh, MD, from Lahey Clinic Medical Center, on Barriers to Multinational Association of Supportive Care in Cancer Guideline Compliance
Dr. RuiRong Yuan, from Daiichi Sankyo, on the Efficacy of Tivantinib for Patietns With Hepatocellular Carcinoma.
Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action
Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.
Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms
Dr. Raoul Concepcion, from Urology Associates, PC, Discusses Urologists Treating Cancer.
Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate
Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T
Paul Jacobsen, from H. Lee Moffitt Cancer Center and Research Institute, Discusses Cancer Survivorship Rehabilitation.
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.
Dr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.
Donna Berry, from Dana-Farber Cancer Institute, on Compliance to Oral Cancer Therapies.
Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.
Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.
Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel
Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival
Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints
Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5